Is Foghorn Therapeutics Inc. (FHTX) a Buy, Sell, or Hold?
Foghorn Therapeutics Inc.
NASDAQ:FHTX
$5.45 USD
$0.07 (1.3%)
- Volume
- 246.55K
- Average Volume
- 226.27K
- Market Capitalization
- $319.99M
- P/E Ratio
- -4.66
- Dividend Yield
- 0.00%
- Price Target
- $12.00
- Year High
- $6.95
- Year Low
- $3.27
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.92
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Adrian H. Gottschalk |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | FHTX |
| CUSIP | 344174107 |
| CIK | 0001822462 |
| Web | https://foghorntx.com |
| Phone | 617 586 3100 |
| Currency | USD |
| Employees | 106 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | -0.55 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.92 |
| Quick Ratio | 2.92 |
| Cash Ratio | 1.38 |
Sales & Book Value
| Annual Sales | $30.91M |
| Price / Sales | 11.34 |
| Cash Flow | -1.26 |
| Price / Cash Flow | -3.66 |
| Price / Book | -4.96 |
Price Target and Rating
| Average Stock Price Forecast | $12.00 |
| High Stock Price Forecast | $12.00 |
| Low Stock Price Forecast | $12.00 |
| Forecast Upside/Downside | -54.58% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 9 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.18 |
| Trailing P/E Ratio | -4.66 |
| PEG Ratio | -0.31 |
| P/E Growth | -0.31 |
| Net Income | $-74.28M |
| Net Margin | -266.88% |
| Pretax Margin | -266.88% |
| Return on Equity | 85.78% |
| Return on Assets | -33.90% |
Financials Score
| AltmanZ Score | -3.83 |
| Piotroski Score | 1.00 |
| Working Capital | 123.66M |
| Total Assets | 222.17M |
| Ebit | -75.32M |
| Market Cap | 302.67M |
| Total Liabilities | 298.58M |
Poll Results
About Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate, and strategize drug development for specific targets within this complex system. Its pipeline includes FHD-286, a small-molecule agent engineered to halt the enzymatic activity of BRG1 and BRM. This compound is being developed to treat metastatic uveal melanoma, as well as acute myeloid leukemia and myelodysplastic syndrome that have either recurred or are resistant to previous therapies. Another key candidate, FHD-609, is a small-molecule protein degrader designed to target ... BRD9, intended for patients diagnosed with synovial sarcoma. Beyond these, Foghorn is also further developing a selective enzymatic inhibitor and a protein degrader, both designed to modulate BRM. Additionally, they are working on ARID1B selective modulators, with potential applications in treating ovarian, endometrial, colorectal, bladder, and gastric cancers. The company has forged strategic alliances, including a research collaboration and licensing agreement with Merck Sharp & Dohme Corp. aimed at unearthing and creating novel oncology therapies focused on a transcription factor target. They also collaborate with Loxo Oncology to devise new cancer treatments. Foghorn Therapeutics Inc. was established in 2015 and maintains its headquarters in Cambridge, Massachusetts.
Foghorn Therapeutics (FHTX) Surges 5.8%: Is This an Indication of Further Gains?
2026-07-03 08:46:03
Foghorn Therapeutics (FHTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Step Pharma announces the appointment of Neil Gallagher as Non-Executive Director
2026-07-01 07:00:00
Neil Gallagher, MD, PhD, joins with over 25 years clinical development experience, having contributed to multiple commercial therapeutics across haematology and oncology His appointment will strengthen Step Pharma's board as it advances dencatistat across three clinical programmes for essential thrombocythaemia (ET), lymphoma and solid tumours.
Step Pharma announces the appointment of Neil Gallagher as Non-Executive Director
2026-07-01 07:00:00
Saint-Genis-Pouilly, France, 1 July 2026 – Step Pharma (“the Company”), the global leader in CTPS1 inhibition for targeted cancer treatment, today announces the appointment of Neil J. Gallagher, MD, PhD, as Non-Executive Director effective immediately. He will support the Company as it continues to advance its first-in-class CTPS1 inhibitor, dencatistat, as a treatment for essential thrombocythaemia, lymphoma and solid tumours.
2026-06-09 16:52:11
Foghorn Therapeutics Inc. (FHTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
2026-06-05 07:00:00
WATERTOWN, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May
2026-05-12 07:00:00
WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the H.C.
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimates
2026-05-07 09:56:00
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.3 per share a year ago.
Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update
2026-05-07 07:00:00
- FHD-909 (LY4050784) Phase 1 dose-escalation trial on track; preclinical combination data with anti-PD-1 antibody demonstrates potential for robust and durable regression with anti-tumor immune memory - Selective CBP degrader FHT-171 advancing for the treatment of ER+ breast cancer with IND anticipated in 2027 -Selective EP300 degraders with potential in multiple myeloma and other hematological malignancies with IND anticipated in 2027 - Strong balance sheet with cash, cash equivalents, and marketable securities of approximately $184 million ; cash runway into the first half of 2028 WATERTOWN, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today provided a financial and corporate update in conjunction with the Company's 10-Q filing for the quarter ended March 31, 2026.
Frequently Asked Questions
-
What is the current Foghorn Therapeutics Inc. (FHTX) stock price?
-
Foghorn Therapeutics Inc.(NASDAQ:FHTX) stock price is $5.45 in the last trading session. During the trading session, FHTX stock reached the peak price of $6.95 while $3.27 was the lowest point it dropped to. The percentage change in FHTX stock occurred in the recent session was 1.3% while the dollar amount for the price change in FHTX stock was $0.07.
-
FHTX's industry and sector of operation?
-
The NASDAQ listed FHTX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of FHTX?
-
Adrian H. Gottschalk | President, Chief Executive Officer & Director
Douglas G. Cole | Founder & Independent Chairman of the Board
Michael J. LaCascia | Chief Legal Officer
Saurabh Sewak | Vice President of Corporate Development
Karin Hellsvik | Chief of Staff to the CEO, VP, Head of Corporate Affairs, Investor Relations & Operations -
How many employees does FHTX have?
-
Number of FHTX employees currently stands at 106. FHTX operates from 500 Technology Square, Cambridge, MA 02139, US.
-
Link for FHTX official website?
-
Official Website of FHTX is: https://foghorntx.com
-
How do I contact FHTX?
-
FHTX could be contacted at phone #617 586 3100 and can also be accessed through its website. FHTX operates from 500 Technology Square, Cambridge, MA 02139, US.
-
How many shares of FHTX are traded daily?
-
The average number of FHTX shares traded daily for last 3 months was 226.27K.
-
What is the market cap of FHTX currently?
-
The market value of FHTX currently stands at $319.99M with its latest stock price at $5.45